5-substituted ornithine derivatives
AssigneeMerrell Dow Pharmaceuticals Inc.
InventorsFritz E. Gerhart, Nikolaus J. Seiler
Life of this patent
Estimating the term…
Abstract
This invention relates to ornithine derivatives substituted at the 5 position with an R group which can be a --CH.sub.2 F, --CHF.sub.2, --CHClF, --C.tbd.CH, --CH.dbd.CH.sub.2, or --CH.dbd.C.dbd.CH.sub.2 group and the pharmaceutically acceptable acid addition salts thereof which are specific inhibitors of OAT and can be used in the treatment of conditional deficiencies of ornithine.
Claims9
A .delta.-substituted ornithine derivative of the formula:
- ##STR13## wherein R is a --CH.sub.2 F, --CHF.sub.2, --CHClF, --C.tbd.CH, --CH.dbd.CH.sub.2, or --CH.dbd.C.dbd.CH.sub.2 group or a pharmaceutically acceptable acid addition salt thereof.
A method of treating a conditional deficiency of ornithine which comprises administering to a patient in need thereof a therapeutically effective amount of a .delta.-substituted ornithine derivative of the formula:
- ##STR14## wherein R is a --CH.sub.2 F, --CHF.sub.2, --CHClF, --C.tbd.CH, --CH.dbd.CH.sub.2, or --CH.dbd.C.dbd.CH.sub.2 group or a pharmaceutically acceptable acid addition salt thereof.
A pharmaceutical composition for treating conditional deficiencies of ornithine which comprises a .delta.-substituted ornithine derivative of the formula:
- ##STR15## wherein R is a --CH.sub.2 F, --CHF.sub.2, --CHClF, --C.tbd.CH, --CH.dbd.CH.sub.2, or --CH.dbd.C.dbd.CH.sub.2 group or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptably carrier.
Dependencies are inferred from the claim text.